Resource Hub - Magnitude Biosciences

Skip to content

VivoScan™ Platform
WormGazer™ Technology
Our Assays
Company
Resources
- All Resources
- FAQ
- Case Studies
- Videos
- Publications
- Brochures
News
Contact

Search for:

VivoScan™ Platform
WormGazer™ Technology
Our Assays
Company
Resources
- All Resources
- FAQ
- Case Studies
- Videos
- Publications
- Brochures
News
Contact

Resource Hub

All our latest resources

Why lower organisms matter for neurodegeneration drug discovery

VivoScan™: Abundant Whole-Organism Data for AI-driven Drug Discovery Pipelines

Let the Worm Wiggle into the Pipeline: The Case for C. elegans in Modern Drug Discovery

magnitude just text (1)

Magnitude Biosciences and BioAscent Discovery Announce Collaboration to Profile Chemogenomics Library Using VivoScan™ Whole-Organism Screening

Tackling the Translational Gap with Whole-Organism HTS

VivoScan™ Data Insight Pack

WormGazer™ Video: Reproductive Toxicity of Etoxazole in C. elegans

WormGazer™ Video: C. elegans Mobility Decline

Magnitude Biosciences secures over £700,000 to accelerate in vivo high-throughput drug discovery platform

C. elegans: a Game Changer for Scalable Gut-Brain Axis Research

Webinar: From Bench to Brand Tackling Healthy Ageing R&D Challenges

Cracking the Rapamycin Problem in C. elegans Ageing Research

Cracking the Rapamycin Problem in C. elegans Ageing Research

Case Study: Helping DailyColors Health Bridge the Gap to Clinical Trials

C. elegans: A Fast, Scalable Model for Microbiome Research

Harnessing AI and C. elegans: Bridging Prediction and Proof in Drug Discovery

2025 Trends and Predictions: Weight Management and Longevity

2025 Trends and Predictions: Gut Health

Publication: New tools to monitor Pseudomonas aeruginosa infection and biofilms in vivo in C. elegans

Personal Care Magazine: Developing Efficient Probiotics in Ageing

Technology Networks: Addressing Key Limitations in Disease Models

Brochure: Pharma & Biotech

IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening With C. elegans

Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with C. elegans

The Nematode Corner: Delaying Forgetting – How Ice and Lithium Affect Memory in C. elegans

Publication: Timut Pepper Extract Slows Age-Dependent Decline of Mobility and Collagen Loss and Promotes Longevity

The Nematode Corner: Toxicity Testing with C. elegans

Brochure: Health & Nutrition

Probiota 2024: Exploring Probiotic Efficacy Beyond CFUs

Case Study: Identifying a lead candidate for slowing ageing with Gerostate Alpha

Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio

The Nematode Corner: Unearthing Nutraceutical Discoveries

Magnitude Biosciences: Revolutionising Research

The Nematode Corner: Powering Industry Progress

Publication: Rapid measurement of ageing by automated monitoring of movement of C. elegans populations

Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant

Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases

AB Biotek works with Magnitude Biosciences to accelerate probiotic development

Case Study: AB Biotek works with Magnitude Biosciences to accelerate probiotic development

Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease

Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Ageing drug discovery biotech sees exciting early in vivo data for lead compound

Podcast: ‘Tiny Worms, Experiments Fast’ on New Matter

Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing

Case Study: Michelin & Magnitude Biosciences

ELRIG Drug Discovery 2021

Publication: Applying C. elegans to industrial drug discovery

Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms

Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand

Could C. elegans be the key to slowing ageing?

Frontiers in Longevity: How do we slow human ageing?

Unlocking the microbiome as a target for drug discovery using C. elegans

C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research

Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting

Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans

Publication: Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety

Publication: Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans

Microbiome SIG Webinar Series

C. elegans Automated Imaging in Drug Discovery

Publication: Health and Longevity Studies in C. elegans: Strengths, Weaknesses, and Gaps

Magnitude Biosciences recognised in ‘Developed in Durham’ as local success story

Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021

A child, a worm, and a new era of drug discovery

The worm angle on the taurine story: A route to the clinic by understanding mechanism

Magnitude Biosciences secures its second round of funding to support its pre-clinical research services

Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris

Magnitude Biosciences announces new hires to support continued growth

Magnitude Biosciences secures UK government Future Fund to expand its workforce

Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and ready to support research

Magnitude Biosciences will be presenting at the online European Worm Meeting

Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd.

Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham University, UK

Our Services

Ageing & Longevity
Microbiome
Neurodegeneration
Toxicity
Transgenics

Who we help

Nutraceuticals & Ingredients
Cosmeceuticals
Biotechnology
Pharma
Academia

Why C. elegans?

WormGazer™ Technology
VivoScan™ Platform

News
Resources
Contact

Company

About Us
Our Team
Testimonials
Jobs

Legal

Privacy
Cookies

© 2025 Magnitude Biosciences Ltd.
Registered in England and Wales under Company Number 11579884. All rights reserved.

Scroll to Top